1. JENTADUETO
Jentadueto is a brand drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for treating type 2 diabetes mellitus. It was approved for market use on Jan 30, 2012. Jentadueto uses Linagliptin; Metformin Hydrochloride as an active ingredient.
Total Patents:
26
Expired Patents:
9
Jentadueto holds 7 exclusivities. Out of these M-295, PED will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| M-252 | Mar 30, 2023 |
| M-146 | Jul 30, 2017 |
| M-295 | Jun 20, 2026 |
| M-258 | Jul 03, 2022 |
| PED | Dec 20, 2026 |
| NCE | May 02, 2016 |
| NC | Jan 30, 2015 |
Check the entire list of patents and their expiration dates for Jentadueto
2. ORENITRAM
Orenitram is a brand drug owned by United Therapeutics Corp. It is Used for treating pulmonary arterial hypertension (WHO Group 1) with oral osmotic pharmaceutical dosage forms of treprostinil. It was approved for market use on Dec 20, 2013. Orenitram uses Treprostinil Diolamine as an active ingredient.
Total Patents:
16
Expired Patents:
7
Orenitram holds 6 exclusivities. Out of these ODE-272 will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| D-157 | Jan 28, 2019 |
| D-156 | Jan 28, 2019 |
| ODE-308 | Dec 20, 2020 |
| I-820 | Oct 18, 2022 |
| ODE-272 | Oct 18, 2026 |
| NDF | Dec 20, 2016 |
Check the entire list of patents and their expiration dates for Orenitram
3. BRUKINSA
Brukinsa is a brand drug owned by Beone Medicines Usa Inc. It is used for treating adult patients with various types of lymphomas and leukemias who have not responded to prior therapies. It was approved for market use on Nov 14, 2019. Brukinsa uses Zanubrutinib as an active ingredient.
Total Patents:
13
Expired Patents:
0
Brukinsa holds 11 exclusivities. Out of these I-817, ODE-276 will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| ODE-371 | Aug 31, 2028 |
| I-817 | Jan 19, 2026 |
| ODE* | Mar 07, 2031 |
| ODE-467 | Mar 07, 2031 |
| I-936 | Mar 07, 2027 |
| ODE-274 | Jan 19, 2030 |
| I-871 | Aug 31, 2024 |
| I-874 | Sep 14, 2024 |
| ODE-370 | Sep 14, 2028 |
| NCE | Nov 14, 2024 |
| ODE-276 | Nov 14, 2026 |
Check the entire list of patents and their expiration dates for Brukinsa
4. ZEPBOUND (AUTOINJECTOR)
Zepbound (autoinjector) is a brand drug owned by Eli Lilly And Co. It is Used for long-term weight management in adults who are overweight or obese with at least one weight-related comorbid condition. It was approved for market use on Nov 8, 2023. Zepbound (autoinjector) uses Tirzepatide as an active ingredient.
Total Patents:
8
Expired Patents:
0
Zepbound (autoinjector) holds 4 exclusivities. Out of these NP will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| NP | Nov 08, 2026 |
| NCE | May 13, 2027 |
| M-82 | Oct 18, 2027 |
| I-958 | Dec 20, 2027 |
Check the entire list of patents and their expiration dates for Zepbound (autoinjector)
5. JARDIANCE
Jardiance is a brand drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is Used for reducing cardiovascular risk and treating type 2 diabetes, heart failure, and chronic kidney disease with empagliflozin. It was approved for market use on Aug 1, 2014. Jardiance uses Empagliflozin as an active ingredient.
Total Patents:
26
Expired Patents:
0
Jardiance holds 11 exclusivities. Out of these PED, NPP, I-922 will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| M-160 | Jun 26, 2018 |
| NCE | Aug 01, 2019 |
| PED | Dec 20, 2026 |
| I-739 | Dec 02, 2019 |
| I-869 | Aug 18, 2024 |
| NPP | Jun 20, 2026 |
| M-161 | Jun 26, 2018 |
| I-922 | Sep 21, 2026 |
| M-82 | Feb 24, 2025 |
| M-159 | Jun 26, 2018 |
| M-174 | Mar 18, 2019 |
Check the entire list of patents and their expiration dates for Jardiance
6. EXPAREL
Exparel is a brand drug owned by Pacira Pharmaceuticals Inc. It is Used for providing local or regional analgesia in various surgical procedures and postoperative pain management. It was approved for market use on Oct 28, 2011. Exparel uses Bupivacaine as an active ingredient.
Total Patents:
26
Expired Patents:
5
Exparel holds 4 exclusivities. Out of these I-929 will expire in 2026. Given below is the list of all its exclusivities and their expiration dates
| Exclusivity Code | Exclusivity Date |
|---|---|
| I-771 | Apr 06, 2021 |
| I-929 | Nov 09, 2026 |
| NPP | Mar 22, 2024 |
| NP | Oct 28, 2014 |
Check the entire list of patents and their expiration dates for Exparel